ArriVent BioPharma (AVBP) Research & Development (2023 - 2026)

ArriVent BioPharma has disclosed Research & Development across 4 years of filings, most recently posting $37.6 million for Q1 2026.

• Research & Development for Q1 2026 came in at $37.6 million, down 38.62% year-over-year; the trailing twelve-month figure through Mar 2026 was $129.7 million (up 5.16% YoY), and the FY2025 annual result was $153.4 million, up 94.11% from the prior year.
• Research & Development came in at $37.6 million for Q1 2026 at ArriVent BioPharma, up from $32.2 million in the prior quarter.
• In the past five years, Research & Development ranged from a high of $61.3 million in Q1 2025 to a low of $10.2 million in Q1 2023.
• The 4-year median for Research & Development is $20.4 million (2023), against an average of $25.8 million.
• Across the five-year window, Research & Development soared 261.05% in 2025 and plunged 38.62% in 2026, its largest moves.
• ArriVent BioPharma's Research & Development stood at $20.0 million in 2023, then grew by 0.76% to $20.2 million in 2024, then surged by 59.57% to $32.2 million in 2025, then grew by 16.91% to $37.6 million in 2026.
• The last three Research & Development figures came in at $37.6 million (Q1 2026), $32.2 million (Q4 2025), and $32.2 million (Q3 2025), per Business Quant data.